This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- The Federal Reserve is not going to get in the way of a good holiday season, Jim Cramer told his "Mad Money" viewers Friday.

That's why Cramer said he'd use any weakness in the market next Wednesday to buy up some of the great stocks that will be put on sale.

Cramer expects the market to weaken on Wednesday ahead of of Thankgiving as it digests the latest unemployment data, durable goods and consumer sentiment numbers. That would be a great time to buy some of the stocks that will be reporting earlier next week, such as Workday (WDAY) and Palo Alto Networks (PANW), both of which report on Monday.

Cramer said the highly valued Workday could get crushed on anything less that a "beat and raise" quarter, but this cloud-based human resource management company is a buy on any weakness. Palo Alto, he said, is also highly valued, but also worth the expense.

Tuesday brings earnings from Hewlett-Packard (HPQ), a stock Cramer said he's liking more now that Dell has none private. He also expects solid results from Tiffany (TIF), Cracker Barrel (CBRL) and DSW (DSW), three stocks that are up 41%, 41% and 81% respectively for the year.

Also on Tuesday, TiVo (TIVO), a stock that's also become a great value.

Cramer said he'd use weakness on Wednesday to picking any of these names.

Riding High Again

The four horsemen of biotech ride again, Cramer told viewers. The stocks of Gilead Sciences (GILD - Get Report), Celgene (CELG - Get Report), Biogen Idec (BIIB - Get Report) and Regeneron (REGN - Get Report) will be the anointed four going into the close of the year.

Cramer said love for the biotechs comes and goes, fizzling late this summer after a rash of red-hot IPOs. But over the past few weeks, the biotechs have once again come into fashion and been red-hot commodities for investors.

Cramer said there's three reasons for the move. First is the continued economic growth, followed by growth overseas and, finally, a host of new drug approvals. All three of these factors will continue these stocks on their current trajectory. Both Gilead and Celgene have seen approvals in the European Union strengthen their stocks while Biogen saw its shares jump $20 just today on a new approval.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $263.12 -3.87%
CELG $100.90 -2.25%
GILD $85.60 -1.80%
REGN $360.64 -2.88%
AAPL $94.19 -1.04%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs